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Introduction 
 
 
In the context of its contribution to monitoring HCV elimination among PWID in Europe, the EMCDDA 
conducted a study on current HCV policies, assessing if and how these refer to people who inject 
drugs (PWID). This document contains a compilation of information about the current HCV policies in 
all EU countries and Norway and short assessments on whether these policies address PWID’s access 
to HCV care. It provides background information for this online publication: 'Viral hepatitis policies in 
Europe' (http://www.emcdda.europa.eu/publications/topic-overviews/hepatitis-policy_en). 
 
For the purpose of this project, “HCV policies” were defined as: national strategies, programmes and 
action plans addressing HCV treatment and care – either in general terms or specifically with regard 
to PWID – including those where viral hepatitis is an integrated part of a broader health strategies or 
plan.  
Between February and October 2017, a targeted search for policy documents was undertaken in 
workbooks on the drug situation and responses submitted by National Focal Points to the EMCDDA, 
published and grey literature, and relevant national websites. Additional information was gathered 
through the EMCDDA expert network on drug-related infectious diseases. To illustrate access of PWID 
to HCV treatment and care, current clinical guidelines, practice and research reports were also 
considered.  
An assessment of whether and how national policies or clinical guidelines address the access of 
people who inject drugs to HCV care and treatment was made and analytical summaries as well as 
lists of national policy-relevant documents were compiled. These were submitted to EMCDDA Focal 
Points in early 2018 for validation and, if necessary, update. The updated material was compiled by 
the EMCDDA and represents the status until March 2018. All countries except Turkey provided 
feedback. 
Country documentation and summaries in this document were originally collected and drafted by 
EMCDDA consultant Stine Nielsen, infectious disease epidemiologist, under contract 
CT.16.IBS.0156.1.0. 
 
Regular updates of the HCV policy landscape are planned to be conducted in the context of the yearly 
meetings of the DRID expert network (next update: Autumn 2018). 
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Austria 
Summary: No national strategy or action plan addressing hepatitis is available and no specific 
guidelines addressing HCV treatment for PWID was identified.  Locally, innovative options for 
the treatment of drug users with chronic HCV are being developed: HCV treatment is 
available both in hospitals in Vienna, Graz and Innsbruck – usually in cooperation with low-
threshold centres – and also directly in the low-threshold setting of the Viennese 
‘Ambulatorium’, as a directly observed therapy combined with opioid substitution treatment. 
Resulting from cooperation with a number of pharmacies, patients undergoing opioid 
substitution treatment at the ‘Ambulatorium’ can receive their hepatitis C medication at the 
pharmacy together with their substitution medicine. Nowadays, health insurance funds cover 
the costs of treatment with new direct-acting antivirals for all patients independent from 
degree of fibroses and genotype. 
 
HCV policy key-document  
 
No specific document addressing national policy of HCV treatment and care for PWID 
identified. 
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Guidelines Gesundheit.gv.at (Öffentliches Gesundheitsportal Österreichs) (2017): 
Hepatitis C – Therapie & Nachsorge [HCV treatment information for 
general public] 
HCV research and 
practice  
Schütz, A. et al. (2018): Directly observed therapy of chronic hepatitis 
C with ledipasvir/sofosbuvir in people who inject drugs at risk of 
nonadherence to direct-acting antivirals. Journal of Viral Hepatology, 
2018 Jan 5. doi: 10.1111/jvh.12857.  ClinicalTrials.gov number, 
NCT02638233  
Haltmayer, H. et al (2016): Directly Observed Therapy of chronic 
Hepatitis C with Interferon-Free All-Oral Regimens at a Low-Threshold 
Drug Treatment Facility – A New Concept for Treatment of Patients 
with Borderline Compliance Receiving Opioid Agonist Therapy. Poster 
at the INHSU 2016, Oslo 
Haltmayer, H. et al (2015): Therapie der chronischen Hepatitis C bei 
Patienten unter Opioid-Substitutionstherapie im niedrigschwelligen 
Setting [Treatment of chronic HCV among patients in opioid 
substitution treatment in low-threshold settings], Suchtmedizin, Vol. 
17, nr. 6, p 267-275. 
Other Gesundheit Österreich (2016): “Datenanalyse zu Inzidenz und 
Prävalenz von Hepatitis-C-Erkrankungen in Österreich” [Analysis of 
prevalence and incidence of HCV-related illness in Austria]  
Sources of 
information 
Feedback on original draft summary received from Irene Schmutterer 
(May 2017), updated and validated by Ilonka Horvath, Head of 
National Focal Point Austria (March 2018). 
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Belgium 
Summary: A national strategic plan to tackle Hepatitis C (2014-2019) was prepared in 2012 
and adopted by the Ministry of Health in May 2014. PWID are mentioned as a priority group 
in the strategic plan. There is no specific budget allocated to implement the action plan and 
no specific targets or concrete plan for monitoring progress towards the actions suggested in 
the plan. The plan includes three overall aims: 1) To reduce transmission of HCV; 2) Increase 
the proportion of HCV infected people who are diagnosed and 3) To improve care for and 
quality of life among people living with hepatitis C. Since the beginning of 2017, an inter-
ministerial working group, representing all the Belgian communities and regions is evaluating 
the national strategic plan and is planning follow-up for those action points that have not 
been implemented yet. The clinical treatment guidelines were updated in 2017 and are 
based on the most recent EASL guidelines. PWID are not mentioned specifically and are 
treated with the same criteria used for non-PWID. 
 
HCV policy key-document  
 
Ministry of Health: Plan Hépatite C 2014-2019 [Hepatitis C plan 2014-2019], adopted on 5 
May 2014. 
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Guidelines The Belgian Association for the Study of the Liver (BASL): “Treatment 
options and diagnostic cut-offs for HCV in Belgium” (Updated January 
2017)  
Bourgeois S et al (2016): “Achieving WHO recommendations for 
Hepatitis C Elimination in Belgium”. Acta Gastro-Enterologica Belgica. 
Vol LXXIX, April-June 2016.  
HCV research and 
practice  
Belgian Health Care Knowledge Center KCE (2012): Health Technology 
Assessment “Hépatite C: Dépistage et Prévention” [Hepatitis C: 
Screening and Prevention] Literature review on the effectiveness and 
cost-effectiveness of HCV screening among PWID and of HCV 
prevention programs among PWID as well as application of a dynamic 
mathematical model to investigate the effectiveness of treating PWID 
(including active PWID) to prevent HCV transmission. 
Matheï C, Bourgeois S, Blach S, Brixko C, Mulkay JP, Razavi H, Robaeys 
G: Mitigating the burden of hepatitis C virus among people who inject 
drugs in Belgium. Acta Gastroenterol Belg 2016, vol.79, pp 227-232. 
Other Muyldermans G , Van Gucht S, Van Baelen L: Jaarrapport 2016 
Hepatitic C Virus. WIV-ISP, Brussels; 2016. 
Sources of 
information 
Input received from Luk Van Baelen, DRID expert of the Belgian 
National Focal Point (March 2018). 
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Bulgaria 
Summary:  No national strategy or action plan addressing hepatitis is available. There is no 
specialised viral hepatitis treatment programme targeting people with addictions or other 
risk groups. The document defining the rules for treatment of viral hepatitis by the National 
Health Insurance Fund limits the access of people with current alcohol and drug abuse to 
treatment (see below). Clients in opioid substitution programmes are only eligible for HCV 
treatment if a psychiatric assessment determines that they are stable and meet certain 
inclusion criteria.  The review of DAA restrictions criteria in Europe performed on behalf of 
the International Network on Hepatitis in Substance Users (INHSU) Network found that 
access to HCV treatment in Bulgaria required “12 month abstinence from drug and alcohol 
abuse” (Marshall et al 2018). 
 
HCV policy key-document  
 
No specific document addressing national policy of HCV treatment and care for PWID 
identified. 
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Guidelines National Health Insurance Fund (March 2017): “Изисквания на НЗОК 
за извънболнично лечение на Хроничен вирусен С хепатит при 
пациенти над 18 годишна възраст в сила” [Requirements for the 
outpatient treatment of chronic viral hepatitis ] 
http://www.nhif.bg/web/guest/207  
This document states: “It is recommended that in patients who are 
expected to have a low level of adherence - especially patients with 
significant alcohol consumption and/or drug abuse, priority should be 
given to resolving the problems of abuse and postponing the 
treatment of hepatitis C until their stabilization.” 
HCV research and 
practice  
 
Other  
Sources of 
information 
Input received from Violeta Bogdanova, DRID expert of the Bulgarian 
National Focal Point (June 2017). 
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Croatia 
Summary: No national strategy or action plan addressing hepatitis is available. Updated 
clinical guidelines for treatment of Hepatitis C were published in May 2017. These mention 
that the latest guidelines from EASL and WHO recommend that all patients with chronic 
hepatitis C who are willing to be treated and have no contraindication should be treated. 
However, they also mention that due to limited availability of DAAs it is currently necessary 
to identify priority groups who will be treated first. The clinical guidelines do not mention 
PWID. The costs of DAA treatment is covered by the national health insurance fund. The 
review of DAA restrictions criteria in Europe performed on behalf of the International 
Network on Hepatitis in Substance Users (INHSU) Network found that access to HCV 
treatment with DAAs in Croatia requires six months abstinence from drug and alcohol abuse 
and toxicological tests every 3 months while on HCV treatment (Marshall et al 2018). 
 
 
HCV policy key-document  
 
No specific document addressing national policy of HCV treatment and care for PWID 
identified. 
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Guidelines Ministry of Health / Reference Centre for diagnosis and treatment of 
viral hepatitis (May 2017): “Preporuke za liječenje hepatitisa C” 
[Recommendations for treatment of hepatitis C] [Last update: 23 May 
2017] 
HCV research and 
practice  
 
Other  
Sources of 
information 
Summary and list of documents validated by Marko Markus, DRID 
expert of the Croatian National Focal Point (March 2018). 
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Cyprus 
 
Summary: No national strategy or action plan addressing hepatitis is available. No specific 
documents addressing HCV treatment for PWID are available. In the harm reduction pillar of 
the new Action Plan for Addressing Dependence on Illicit Substances and the Harmful Use of 
Alcohol (2017-2020) a specific action involving the Ministry of Health stipulates that people 
with substance dependence issues have free access to treatment for infectious diseases in 
public hospitals (Priority 7, Objective 1, Action 6). Free testing for HIV, HBV, HCV and 
tuberculosis for drugs users is available (Circular of Ministry of Health issued in 2011 and 
updated in 2017). HCV treatment guidelines: According to the Ministry of Health, the criteria 
for initiating the new antiviral treatment for Hepatitis C limit access to patients with rapid 
deterioration of liver disease. It is expected that no more than 20 cases will meet the access 
conditions every year. A Technical Mission on Viral Hepatitis B and C of ECDC and WHO 
experts took place in January 2018. A possible future extension of the new antiviral 
treatment for HCV by State Hospitals to specific high risk groups, such as intravenous drug 
users, may be discussed following the adoption of a National Hepatitis Strategic Plan. The 
review of restrictions for reimbursement of DAAs in Europe performed on behalf of the 
International Network on Hepatitis in Substance Users (INHSU) Network found that access to 
DAAs in Cyprus requires abstinence from drug and alcohol abuse (Marshall et al 2018). 
 
HCV policy key-document  
 
No specific document addressing national policy of HCV treatment and care for PWID 
identified. 
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Guidelines Ministry of Health (2014) ΠΡΩΤΟΚΟΛΛΟ ΕΛΕΓΧΟΥ ΜΟΛΥΣΜΑΤΙΚΩΝ 
ΑΣΘΕΝΕΙΩΝ (HIV/AIDS, ΗΠΑΤΙΤΙΔΑ Β & C, ΦΥΜΑΤΙΩΣΗ, ΣΥΦΙΛΗ, 
ΣΑΛΜΟΝΕΛΛΑ ΚΑΙ ΠΑΡΑΣΙΤΑ) [Protocol for the control of infectious 
diseases – including hepatitis C].  
HCV research and 
practice  
 
Other Ministry of Health (2017) Updated circular on free testing for 
infectious diseases for drug users. 
Cyprus National Addictions Authority (2017) Action Plan for 
Addressing Dependence on Illicit Substances and the Harmful Use of 
Alcohol 2017-2020. 
Sources of 
information 
Feedback received from Evi Kyprianou and validated by Ioanna 
Yasemi, Head of the National Focal Point for Cyprus, March 2018. 
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Czech Republic 
 
Summary: No national strategy or action plan addressing hepatitis is available. The clinical 
guidelines on diagnosis and treatment for hepatitis C include the statement that HCV 
treatment must not be refused due to addiction. 
 
 
HCV policy key-document  
 
No specific document addressing national policy of HCV treatment and care for PWID 
identified. 
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Guidelines Urbánek et al 2017: “STANDARDNÍ DIAGNOSTICKÝ A TERAPEUTICKÝ 
POSTUP CHRONICKÉ INFEKCE VIREM HEPATITIDY C (HCV)” [National 
guidelines for HCV diagnostic and treatment] (From March 2017) 
 
HCV research and 
practice  
 
Other The Czech National Monitoring Centre for Drugs and Addiction: 
National Drug Policy Strategy for the period 2010-2018  
PWID access to HCV treatment and care not addressed specifically in 
this drug policy strategy, only the general objective to decrease and 
treat infections among PWID is mentioned. 
Sources of 
information 
Feedback on summary and list of documents received from Barbara 
Janikova and validated by Viktor Mravcik, Head of National Focal Point 
Czech Republic (February 2018). 
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Denmark 
 
Summary: In 2007, the national board of health published a national action plan for 
preventing hepatitis C among people who use drugs. This was followed up in 2013 with a 
general guidance on HIV, HBV and HCV for health care workers which included a section on 
ensuring testing, counselling and care (i.e. HBV vaccination) for people in drug treatment 
(e.g. in OST). 
 
 
HCV policy key-document  
 
Sundhedsstyrrelsen 2013: “Vejledning om HIV (human immundefekt virus), hepatitis B og C 
virus” [Guidance for HIV (human immunodeficiency virus), hepatitis B and C virus] 
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Epidemiology  
Guidelines Weis N et al 2017: “Behandling af hepatitis B virus (HBV) og hepatitis C 
virus (HCV) infektion – En guideline” (Dansk Selskab for 
Infektionsmedicin & Dansk Selskab for Gastroenterologi e Hepatologi); 
” [Treatment guidelines for HBV and HCV]  
 
HCV research and 
practice  
RADS (Rådet for Anvendelse af Dyr Sygehusmedicin) 2016: 
“Baggrundsnotat for behandling af kronisk hepatitis C infektion“ 
[Background note on treatment of chronic hepatitis C] 
 
Other Sundhedsstyrrelsen 2007: “National handlingsplan til forebyggelse af 
hepatitis C blandt stofmisbrugere” [National action plan for 
preventing HCV among people who use drugs]  
 
Sources of 
information 
List of documents reviewed for completeness by Jan Fouchard, DRID 
expert of the Danish National Focal Point (March 2018). 
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Estonia 
 
Summary: No official national hepatitis policy document (strategy or action plan) currently 
exists. However, despite current (2010) clinical treatment guidelines mentioning PWID as a 
“non-priority group” for HCV treatment, it was reported that in practice HCV treatment is 
available for PWID, but only if they have health insurance. 
 
 
HCV policy key-document  
 
No specific document addressing national policy of HCV treatment and care for PWID 
identified. 
 
 
Additional documents illustrating access of PWID to HCV treatment and care:  
Epidemiology  
Guidelines Estonian Society of Gastroenterology and Estonian Society for 
Infectious Diseases, 2010: „Treatment guidelines for chronic Hepatitis 
C“ . PWID are currently mentioned as a “non-priority patient group” 
(which should not receive antiviral treatment for HCV). However, new 
clinical guidelines are in preparation in which access to HCV treatment 
for PWID will be adapted to reflect international recommendations.  
Estonian Society of sexually transmitted infections, 2015: “Seksuaalsel 
Teel Levivate Infektsioonide Ravijuhis Eestis 2015” [Guidelines on 
sexually transmitted infections] . Includes a section on viral hepatitis 
in which the EASL 2014 guidelines on management of hepatitis C 
infection is referenced.  
HCV research and 
practice  
 
Other Maimets M et al. (2017): “C-hepatiidi epideemia 
likvideerimisstrateegia eesmärgid ja tegevusplaan Eestis aastaiks 
2018–2030. Eesti Gastroenteroloogide Seltsi ja Eesti 
Infektsioonhaiguste Seltsi visioon” (Estonian Society of 
Gastroenterology and Estonian Society for Infectious Diseases) 
[“Visions for an Estonian hepatitis C elimination strategy, 2018-2030”]  
This paper has not yet been adopted as an official recommendation in 
Estonia. 
Ministry of Social Affairs: “National Health Plan 2009-2020” 
The national drug strategy and all related activities are described in 
the National Health plan. The Plan does not mention specific activities 
regarding hepatitis among PWID. 
Sources of 
information 
Feedback received from Aljona Kurbatova, Maris Salekešin and Kristel 
Kivimets, DRID experts of the National Focal Point for Estonia, March 
2018. 
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Finland 
 
Summary: A national strategy for hepatitis C for Finland 2017-2019 was published by the 
Ministry of Social Affairs and Health in November 2016. The national strategy was produced 
by a multidisciplinary working group with members from the Ministry of Social Affairs and 
Health; the National Institute for Health and Welfare; Prison health authorities; NGOs; 
Clinicians and the Liver Patient organization.  Finland’s strategy emphasizes that all people 
with hepatitis C infection should have equal access to treatment. The aims of the strategy are 
to: increase prevention of new infections, harmonize diagnostics and treatment practices, 
make a clear clinical pathway from testing to treatment evaluation and therapy, increase 
surveillance, and create a national treatment registry. Treatment guidelines included in the 
strategy specify that DAAs are to be used if the interferon therapy is not effective and liver 
damage is progressing or if there is a contraindication for interferon therapy and the liver 
damage is advanced (F2-F4). Patients who have a contraindication for interferon therapy (e.g 
PWID) must be referred to evaluation of the degree of liver damage and treated if the patient 
is motivated.  In the long term all patients infected with hepatitis C virus would receive 
treatment regardless of the degree of liver damage. In March 2017, the Ministry of Social 
Affairs and Health set up a national HIV and Hepatitis Expert Group with the mandate to 
follow-up the implementation of the hepatitis C strategy. One of its working groups is 
elaborating recommendations on the pathway from testing to treatment evaluation and 
therapy, expected to be published during spring/autumn 2018. Work on HCV treatment 
registry is underway and centralised procurement for HCV DAA’s is taking place. A HCV 
prevalence study among general population (nested HCV study) is underway and hepatitis C 
awareness campaigns are scheduled to take place during 2018. 
  
HCV policy key-document  
 
 Ministry of Social Affairs and Health (Nov 2016): “Suomen C-hepatiittistrategia 2017–2019” 
(Finland’s strategy for hepatitis C 2017-2019)  
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Epidemiology  
Guidelines See strategy 
HCV research and 
practice  
 
Other  
Sources of 
information 
Summary validated by Henrikki Brummer-Korvenkontio, DRID expert 
at the Finnish National Focal Point (March 2018). 
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France 
Summary:  In 1999, France published its first national action plan for hepatitis C 1999-2002, 
which was followed by three further plans until 2012. Since 2013, based on an evaluation by 
the High Council for Public Health (HCSP), viral hepatitis is integrated in the National sexual 
health strategy (2017-2030) to achieve synergy, consistency and a global approach. It is also 
addressed in the 2013-2017 Government Plan for combatting drugs and addictive 
behaviours. France has globally been highlighted as a best practice example for ensuring 
universal access to hepatitis care and treatment also for direct treatment access of people 
who inject drugs. Since June 2016, the National Health Insurance Fund reimburses 100% of 
the cost of treatment with DAAs for current drug users in contact with low threshold who 
exchange their equipment, irrespective of the stage of fibrosis. 
 
HCV policy key-documents  
 
Ministère des affaires sociales et de la santé (2017). Stratégie nationale de santé sexuelle. 
Agenda 2017-2030. Paris, Ministère des affaires sociales et de la santé, 75p. [National sexual 
health strategy] . 
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Guidelines AFEF (March 2017). Recommandations AFEF sur la prise en charge des 
hépatites virales C. AFEF (Association française pour l'étude du foie), 
Paris [Recommendations for the management of HCV infection] . 
ANRS and CNS (2016): “Prise en charge thérapeutique et le suivi de 
l’ensemble des personnes infectées par le virus de l’hépatite C” [2016 
Treatment recommendations for hepatitis C infections] . 
Direction de l'Evaluation Médicale, Economique et de Santé Publique 
Haute Autorité de Santé. Antiviraux d’action directe. In : Commission 
de la transparence, ed. Saint-Denis : HAS, June 2016. 
HCV research and 
practice  
Haute Autorité de santé (HAS) (2016). Commission de la 
Transparence. Rapport d’évaluation des antiviraux d’action directe 
dans le traitement de l’hépatite C. 
Delarocque-Astagneau et al (2010): The impact of the prevention 
programme of hepatitis C over more than a decade: the French 
experience. J Viral Hepat. 2010, 17: 435-443. 
Other MILDECA (2013) Plan gouvernemental de lutte contre les drogues et 
les conduites addictives 2013-2017.Paris, Mission interministérielle de 
lutte contre les drogues et les conduites addictives. [Government Plan 
for Combating Drugs and Addictive Behaviours] 
CNS - Conseil national du SIDA et des hepatites virales (2016): “Créer 
les conditions d’un accès universel aux nouveaux traitements contre 
le virus de l’hépatite C” [Statement on creating conditions for 
universal access to the new hepatitis C treatments] . 
Sources of 
information 
Summary and list of documents validated by Anne-Claire Brisacier, 
DRID expert at the French National Focal Point (March 2018). 
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Germany 
Summary: In 2016, an overall integrated strategy for HIV, hepatitis B/C and other sexually 
transmitted infections was published by the Ministry for Health. It is a general strategy 
without any specific targets. PWID and prisoners are specifically mentioned and the need for 
improved integration of hepatitis testing and treatment (including HBV vaccination) in 
addiction treatment services is highlighted. Recommendations to screen PWID for hepatitis C 
are included in clinical guidelines, but no national screening strategy exists. Access to DAA 
treatment is not restricted in Germany. The treatment costs are covered for all individuals 
with social health insurance, including PWID, if clinical guidelines are followed. Treatment is 
also available in prisons, however medical care of prisoners is funded by the Ministries of 
Justice of the federal German states, and great variation in access to HCV treatment between 
federal states and prisons is observed. 
 
HCV policy key-document  
 
Bundesministerium für Gesundheit (2016): Strategie zur Eindämmung von HIV, Hepatitis B 
und C und anderen sexuell übertragbaren Infektionen. BIS 2030 – Bedarfsorientiert · 
Integriert · Sektorübergreifend [Integrated strategy for HIV, hepatitis B and C and other 
sexually transmitted infections]. The document is available in both German and English. 
 
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Guidelines DGVS (2016): “Aktuelle Empfehlungen zur Therapie der chronischen 
Hepatitis C” [HCV treatment guidelines] 
HCV research and 
practice  
 
Other The 2010 Guidelines on the management of HCV infection are 
currently under revision and expected to be published soon. 
 
Sources of 
information 
Feedback received from Ruth Zimmermann, Robert Koch Institute 
(May 2017). 
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Greece 
Summary: On 28 July 2017, the Ministry of Health launched the first national “Action Plan for 
responding to Hepatitis C among PWID, prisoners, sex workers, men who have sex with men, 
refugees and immigrants in Greece”. The plan promotes early diagnosis and monitoring. The 
strategic goals are a) public awareness on Hepatitis C prevention and response, b) 
development / improvement of health services providing care and treatment for HCV 
infection, c) development of a network of competent health services which are going to 
cooperate with the ECDC and the EMCDDA for monitoring Hepatitis B and C, d) registering all 
HCV positive cases and mapping out all competent health and diagnostic services as a basis 
for the development of evidence-based health policy. The Action Plan will be coordinated by 
the Ministry of Health. The actions will be monitored by the National Coordination 
Committee which consists of: Hellenic Centre for Diseases Control and Prevention (HCDCP ), 
National Scholl of Public Health, General Secretariat for Gender Equality, General Secretariat 
for Young People, Universities, KETHEA, OKANA, 18 ANO, Alternative Therapeutic Programme 
for Drug-addicted Individuals ARGO, science associations (e.g. Hellenic Association for the 
Study and Control of AIDS) and NGOs supporting people living with HCV. 
 
HCV policy key-document  
 
Action Plan for responding to Hepatitis C among PWID, prisoners, sex workers, men who have 
sex with men, refugees and immigrants in Greece 
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Guidelines Hellenic Center for Disease Control and Prevention (February 2017) 
[Treatment Guidelines for Hepatitis C]. Athens: Hellenic Center for 
Disease Control and Prevention (29 pages). PWID should be tested for 
anti-HC and those tested anti-HCV-negative should be re-tested 
annually. Furthermore PWID who are HCV-positive should receive 
priority IFNa-free treatment. 
HCV research and 
practice  
Souliotis K et al 2017: Access to treatment for Hepatitis C among 
injection drug users: results from the cross-sectional HOPE IV study. 
International Journal for Equity in Health (2017) 16:101. 
Gountas I et al 2017: Treatment and primary prevention in people 
who inject drugs for chronic hepatitis C infection: is elimination 
possible in a high-prevalence setting? Addiction, 112(7): 1290-1299. 
Greek Organization against Drugs (OKANA), Framework for the 
Operation of Treatment Facilities (2012). Recommends screening 
upon entry to treatment and referral to appropriate services.  
Other A National Hepatitis Treatment Registry is operational since April 
2017. Registration of patients is obligatory.   
Ministry of Justice (2014) The Greek Charter on the Rights of People 
addicted to Drugs. Makes references to HCV-positive drug users’ right 
for unhindered access to specialised treatment.  
Sources of 
information 
The list of documents was reviewed and updated by Anastasios Fotiou 
(May 2017). 
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Hungary 
 
Summary: In Hungary there is no national HCV strategy. There is a so-called ’consensus 
paper’ on hepatitis C management which is updated yearly as well as a financing protocol – 
these are used in practice by the Health Insurance Fund and the clinicians (the official 
Gastroenterologists’ Association). A separate budget (of around 17 million EUR) has been 
established under the national health insurance fund. Currently, around 4000 people are 
initiating treatment each year and as waiting lists have been reduced, patients can enter 
treatment immediately. DAAs are the first line treatment and the cost per treatment is under 
4000 EUR. The allocated budget is sufficient for all the patients seeking treatment. Screening 
efforts are emphasized as necessary to include more patients, risk groups including drug 
users are recommended to get screened. The official funding protocol in the hepatitis 
register requires from people with drug addiction a three-month period of abstinence before 
initiating treatment. Guidelines require that an addiction specialist’s (psychiatrist) opinion 
should be sought to assess comorbidities such as depression or other psychiatric disorders 
which may be contraindications for treatment. In practice, the decision regarding initiation of 
treatment lies with the hepatologist. An important remaining barrier for IDUs is their lack of 
health insurance rights.  
 
HCV policy key-document  
 
No specific document addressing national policy of HCV treatment and care for PWID 
identified. 
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Guidelines National consensus guideline in Hungary from 22 September 2017 (abstract 
available in EN) 
HCV research and 
practice  
 
Other Hepatitis Register (restricted access)  
A hepatitis C vírus okozta krónikus májgyulladás diagnosztikájának és 
kezelésének finanszírozási eljárásrendje” (2017) [Funding procedure 
for the diagnosis and treatment of chronic hepatitis C] 
Sources of 
information 
Feedback received from Gergely Horváth (August 2017, March 2018) 
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Ireland 
 
Summary:  The first national hepatitis C strategy 2011-2014 published in 2012 did not include 
any extra budget for implementation. After an expert advisory group had examined the 
feasibility of a multi-annual treatment plan for hepatitis C in their report: “Public health plan 
for the pharmaceutical treatment of hepatitis C” (2014), the Government approved the 
establishment of a National Hepatitis C Treatment Programme for 2016-2026 in the Health 
Service Executive (HSE) in line with the approach set out in the report. The National Hepatitis 
C Treatment Programme is managed by a fulltime Programme Manager and is led clinically by 
a Clinical Lead. In July 2017, comprehensive National Clinical Guidelines on Hepatitis C 
Screening were published. Access to HCV treatment is currently provided through specialist 
services based in the acute hospital setting. PWIDs are not restricted or excluded from 
treatment once clinically prioritised by their clinician. On a pilot basis, the HSE has started 
providing HCV treatment in the addiction services setting to patients in opioid substitution 
treatment.  The HSE plans an expansion of HCV treatment across community and acute 
hospital settings in 2018. 
 
HCV policy key-document  
 
Health Service Executive (HSE): National Hepatitis C Treatment Programme 2016-2026 
(website) – for an overview, see Tait (2018): National Hepatitis C Treatment Programme  
 
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Guidelines Department of Health (2017): Hepatitis C Screening (NCEC National 
Clinical Guideline No. 15) . 
Department of Health (2015): Public Health Plan for the 
Pharmaceutical treatment of Hepatitis C .  
HCV research and 
practice  
  
Other Health Service Executive (HSE): National Hepatitis C Strategy 2011-
2014 
Sources of 
information 
Feedback received from Michele Tait, Brian Galvin and Lelia Thornton 
(August/September 2017). 
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Italy 
 
Summary: The latest national plan for prevention of hepatitis B and C was published in 2015. 
It does not include specific targets regarding PWID and no government body is in charge of 
monitoring its implementation. HCV treatment is provided regardless of individual history on 
drug use meaning that PWID are treated with the same criteria used for non-PWID.  
New guidelines for screening and diagnosis of infectious pathologies related to the use of 
substances at the dedicated Addiction care services were published in 2017. 
 
 
HCV policy key-document  
 
Ministry of Health (2015): “PIANO NAZIONALE PER LA PREVENZIONE DELLE EPATITI VIRALI da 
virus B e C (PNEV)” [National plan for prevention of viral hepatitis B and C]  
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Guidelines Luzi A.M. and Suligoi B. Nuove linee di indirizzo per lo screening e la 
diagnosi delle principali patologie infettive correlate all’uso di 
sostanze nei servizi per le dipendenze (New Guidelines for screening 
and diagnosis of the main drug-related infectious diseases at the 
Facilities for Addiction Care). 
HCV research and 
practice  
 
Other Ministry of Health (2017): Epatite C, uso terapeutico di farmaci 
interferon free 
Sources of 
information 
Input provided by Barbara Suligoi, updated and validated by the 
Italian National Focal Point in March 2017. 
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Latvia 
 
Summary: On 31 October 2017, a national action plan addressing HIV, STIs and viral hepatitis 
was adopted in Latvia and funding been allocated for its implementation: 22.7 mio Euro for 
activities in 2018 and 58 mio Euro for 2019-2020 – with most of the funding allocated to 
scale up access to HIV and HCV treatment.  While the plan does not include a specific target 
regarding PWID, it addresses the group through several specific activities, including: the 
creation of new facilities; expansion of outreach staff; improved liaison between harm 
reduction and wider health care services; targeted vaccination of risk groups; scaling up of 
needle and syringe provision; introduction of new treatment options for opioid dependence; 
elaboration of information materials on HIV, STI, HBV, HCV prevention and treatment for 
PWID. The plan includes the elaboration of guidelines for primary care doctors regarding 
treatment of HCV and HIV; as well as the scaling up of treatment of HIV and HCV infection 
among people in prison. The 2017 national guidelines on diagnosis and treatment of chronic 
hepatitis C do not mention PWID specifically. A national HCV treatment registry was initiated 
in 2016 in paper format and since January 2017 it is operational electronically. 
 
 
HCV policy key-document  
 
Ministry of Health. “Action Plan for the Elimination of HIV Infection, Sexually Transmitted 
Infections and Hepatitis B and C for 2018–2020” adopted by the government on 31.10.2017   
 
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Guidelines Ministry of Health. The National Health Service. (Jan 2017) “C 
VĪRUSHEPATĪTA RACIONĀLAS FARMAKOTERAPIJAS REKOMENDĀCIJAS 
ZĀĻU IEGĀDES KOMPENSĀCIJAS SISTĒMAS IETVAROS.” [Hepatitis C 
treatment guidelines]. Document does not specifically address PWID 
access to HCV treatment and care. 
HCV research and 
practice  
 
Other  
Sources of 
information 
Feedback received from: Anda Kivite (November 2017). 
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Lithuania 
 
Summary: No national strategy or action plan addressing hepatitis is currently implemented, 
but a national hepatitis prevention strategy is in the planning stage. The national guidelines 
on diagnosis and treatment of chronic hepatitis C do not mention PWID specifically. HCV 
treatment is administered irrespective of whether the patient is a drug user or not – there 
are no specific restrictions for PWID, but it is unknown how many drug users are treated.  
Hepatitis C testing is foreseen in the framework of a health examination for people starting 
opioid maintenance treatment. The costs for one HCV test per patient prescribed by general 
practitioners or by medical doctors providing primary outpatient mental health care services 
is covered by the national health insurance funds. 
 
 
HCV policy key-document  
 
No specific document addressing national policy of HCV treatment and care for PWID 
identified. 
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Guidelines Ministry of Health (updated an consolidated),2016: “DĖL LĖTINIO 
VIRUSINIO C HEPATITO DIAGNOSTIKOS IR AMBULATORINIO GYDYMO 
KOMPENSUOJAMAISIAIS VAISTAIS TVARKOS APRAŠO TVIRTINIMO” 
[Guidelines for diagnosis and treatment of chronic hepatitis c] . 
HCV research and 
practice  
 
Other Eurasian Harm Reduction Network (2013): Current situation regarding 
access to hepatitis C treatment in Eastern Europe and Central Asia 
[Lithuania is the only EU country included in this report]  
Sources of 
information 
Input received from Ieva Vaitkevičiūtė and Irma Čaplinskiene and 
validated by Lithuanian National Focal Point (March 2018). 
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Luxembourg 
 
Summary: A National Action Plan against Hepatitis (PANHEL), including access to HCV 
treatment and care for PWIDs (EASL guidelines), covering the period from 2018 to 2022 has 
been launched by the Ministry of Health in December 2017. Main five strategic axes of the 
national action plan against viral hepatitis are the following: Assessment of current situation 
and needs, Reduction of incidence of hepatitis, promotion of screening, access to health care, 
and surveillance, research and evaluation. National coordination will be put in place to 
ensure the implementation of the action plan and will be responsible for regularly reporting 
progress indicators and proposing potential improvements to the plan and its 
implementation. In addition to treatment costs, it is estimated that a total budget of 10 mio € 
is required to achieve the specific objectives and priority actions under five strategic axes 
during the 5-year period. 
 
 
HCV policy key-document  
 
Ministère de la Santé Plan d’action national de lutte contre les hépatites au Grand-Duché de 
Luxembourg 2018 - 2022 (PANHEL) 
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Guidelines Arendt V 2017 Treatment guidelines for viral hepatitis in Luxembourg. 
VHPB meeting 8 November 2017 (ppt). 
HCV research and 
practice  
 
Other Arendt V 2017 National action plan against viral hepatitis in 
Luxembourg. VHPB meeting 8 November 2017 (ppt).   
Sources of 
information 
Information updated by Alain Origer (March 2018). 
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Malta 
 
Summary:  On 14 February 2018, a national strategy for the elimination of the hepatitis C 
virus was launched for a 30-day public consultation period by Health Minister Chris Fearne. 
People who use drugs are mentioned as key population to be specifically targeted; 
prevention measures are clearly specified, but no PWID specific targets are defined. The 
strategy document does not include information on budget allocation. Early diagnosis and 
screening for high-risk groups will be introduced; about 200 patients are expected to be 
treated for free annually, treating everyone eventually.  Before then, no standard 
procedures, protocols, or documents were available which address diagnosis, referral to 
treatment and provision of treatment to patients (incl. PWID) with hepatitis C in Malta. 
Treatment for Hepatitis C included interferon treatment (alone and in combination with 
ribavirin). Current drug users with chronic Hepatitis C were not eligible for treatment as 
abstinence and termination of methadone treatment for at least one year were required. 
 
HCV policy key-document  
 
A National Strategy for the Elimination of Hepatitis C Virus as a Public Health Threat in the 
Maltese Islands 2018-2025 (online consultation February 2018) 
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Guidelines  
HCV research and 
practice  
 
Other  
Sources of 
information 
Input received from Carlo Olivari D'Emanuele, Moses Camilleri and 
Tanya Melillo and validated by the Maltese National Focal Point in 
March 2018. 
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Netherlands 
 
Summary: The national hepatitis plan “screening and beyond” officially launched in 
November 2016 was developed by a multidisciplinary commission representing all relevant 
stakeholders involved in research, treatment, prevention and control of hepatitis B and C. 
The plan focuses on five themes: 1) awareness and vaccination, 2) identification, 3) 
diagnostics and offering adequate treatment, 4) improved organization of the continuum of 
care and 5) improved surveillance including improved monitoring of the HBV and HCV 
cascade of care.  HCV treatment is provided regardless of individual history on drug use 
meaning that PWID are treated with the same criteria as non-PWID. The implementation of 
the National Hepatitis Plan is being boosted by the installation of a steering committee with 
representatives from professionals in the field (hepatologists, infectiologist, addiction care 
doctors, GPs), members from the National Institute for Public Health and the Environment 
(RIVM), municipal health services and Trimbos Institute (and Focal Point). This steering 
committee described in 2017 the practical steps needed to implement the National Hepatitis 
Plan and the advice of the Health Council and will, during the coming years, follow up and 
coordinate joined efforts in the implementation of the care path for chronic hepatitis. 
 
HCV policy key-document  
 
RIVM (2016): “Meer dan opsporen. Nationaal hepatitisplan: een strategie voor actie” 
[“Screening and beyond - National hepatitis plan: a strategy for action”]  
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Guidelines NIV, NVHB, NVMDL, NVH, NVZA (2017): Richtsnoer behandeling 
hepatitis C infectie [Guidelines for treatment of hepatitis C – updated 
June 2017]  
RIVM (2016): “Opsporing en herevaluatie van ooit gediagnosticeerden 
met chronische hepatitis B en C. Handreiking regionale aanpak” 
[Guidance on detection and reassessment of chronic hepatitis B and C 
cases. A regional approach.]  
Health Council of the Netherlands. Screening risk groups for hepatitis 
B and C. The Hague: Health Council of the Netherlands, 2016; 
publication no.2016/16. 
RIVM (2012): “LCI-richtlijn Hepatitis C” [Hepatitis C guidelines. 
(General guideline on diagnosis, treatment and prevention)]  
HCV research and 
practice  
 
Other Health Council of the Netherlands (1997): Committee on Hepatitis C. 
Detection and treatment of people with hepatitis C. Rijswijk: Health 
Council of the Netherlands, 1997; publication no. 1997/19. 
Sources of 
information 
Feedback received from Esther Croes (July 2017). 
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Norway 
 
Summary: The national strategy plan against viral hepatitis was published by the Ministry of 
Health in June 2016. It is a brief (6 page) document which mentions three overall goals: 1) 
transmission of viral hepatitis should be kept at the current low level; 2) transmission among 
key populations should be reduced and 3) everyone with liver disease should have access to 
safe and effective treatment. The need for interventions and access to care for PWID is 
mentioned specifically in the plan. The national strategy plan is currently under revision, in 
order to reflect that since February 2018, following the price drop of direct-acting antiviral 
medication, all people who are infected with HCV, regardless of genotype, to receive this 
type of treatment.    
 
 
HCV policy key-document  
 
Ministry of Health and Care: Nasjonal strategi for arbeidet mot virale leverbetennelser 
(hepatitter) - June 2016  [National strategy plan against viral hepatitis] 
 
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Guidelines Norwegian Medical Association (2017): Faglig veileder for oppfølging 
og behandling av hepatitt C. [Guidelines for treatment of hepatitis C – 
updated March 2017]   
HCV research and 
practice  
 
Other Forskrift om helseforetaksfinansierte reseptlegemidler til bruk utenfor 
sykehus [Regulations financing treatment of hepatitis C for patients 
outside hospitals – July 2015]  
Innstilling fra helse- og omsorgskomiteen om Opptrappingsplanen for 
rusfeltet (2016–2020) [From the committee on health and care: Plan 
of action for the area of addiction - Approved April 2016] 
Sources of 
information 
Input received from Hans Blystad, validated and updated by Thomas 
Anton Sandøy, Head of the Norwegian National Focal Point in March 
2018. 
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Poland 
 
Summary: No official strategy or action plan addressing viral hepatitis exists. The current 
National Plan for Drugs Prevention which is integrated into the National Health Plan 2016-
2020 mentions the importance of access to harm reduction (substitution therapy and needle-
syringe exchange) and increased uptake of infectious disease testing for PWID. There is no 
mention of access to HCV treatment for PWID. The work on a National strategy for viral 
hepatitis was initiated in 2006 but hampered by the lack of epidemiological evidence. The 
latest background documents were provided to the Ministry of Health by clinical experts in 
2015 and by the National Institute of Public Health in mid-2017 and are now being processed 
in order to produce a National Strategy. In the current guidelines for the national HCV 
treatment programme it is mentioned that people who are actively dependent on a 
psychoactive substance are excluded from HCV treatment. Routinely offered HCV testing 
within harm reduction services is also not yet implemented at national level – under the 
national Drug Prevention Bureau two initiatives (both in Warsaw) have recently been 
launched to improve HCV testing among PWID. 
 
HCV policy key-document  
 
No specific document addressing national policy of HCV treatment and care for PWID 
identified. 
 
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Guidelines  
HCV research and 
practice  
Halota et al 2016: “Recommendations for the treatment of hepatitis C 
issued by the Polish Group of HCV Experts – 2016.” Clinical and 
Experimental HEPATOLOGY 2016; 2: 27–33. This document does not 
specifically address PWID access to HCV treatment but mentions: “All 
patients with chronic HCV infection should receive treatment. The 
sooner the therapy is initiated, the better the outcome and the lower 
the cost.”  
Other National Health Programme (August 2016): National Health Plan 
2016-2020 includes the National Plan for Drug Prevention.  
Ministry of Health website: Programy lekowe [Information on the 
national treatment programs] 
 
Sources of 
information 
Feedback received from Magdalena Rosińska (June/September 2017). 
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Portugal 
 
Summary: Following intense advocacy efforts by civil society and the scientific community, 
the Portuguese Ministry of Health announced in February 2015 that the government would 
provide universal access to DAA treatment for all patients with chronic hepatitis C. An 
arrangement with a pharmaceutical company producing DAAs adopting a ‘risk sharing’ model 
together with a volume-based agreement was found. This meant that the Ministry pays per 
patient clinically cured (not per weeks of treatment, nor per patients treated), and that the 
price paid is inversely proportional to the number of patients treated. A national electronic 
HCV treatment registry has been setup and is used by all physicians prescribing DAAs. The 
latest national HCV treatment guidelines were updated in 2015. In July 2017, the Ministry of 
Health published the first report on the National programme for viral hepatitis 2017, the first 
national strategic plan of the health sector response to viral hepatitis. The document does 
not include specific targets and does not address resources for implementation.  Also in July 
2017, governmental order 6542/2017  determined that the design and implementation of 
prevention, diagnosis and treatment of infectious diseases, such as HIV and viral hepatitis 
among the prisoner population should be equivalent to other users of the national health 
system. Following this, a referral network for HIV and viral hepatitis care for the inmate 
population was established per governmental order 283/2018 in January 2018. 
 
HCV policy key-document  
 
Ministry of Health (July 2017): “Programa Nacional para as Hepatites Virais 2017 ” [National 
programme for viral hepatitis - report 2017]   
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Guidelines Ministry of Health: “Tratamento da Hepatite C Crónica no Adulto” 
[Guidelines for treatment of hepatitis C] – regularly updated 
HCV research and 
practice  
Leite RB (2014): Consensus for the integrated management of 
hepatitis C in Portugal. BMC Infectious Diseases 2014 14(Suppl 6):S9 
EATG (2016) report: Access to highly effective hepatitis C treatment in 
Portugal A Community Perspective. 
Rodrigues et al (2016). Evidence of impressive real-world SVR from 
the Portuguese ledipasvir/sofosbuvir and sofosbuvir universal 
coverage programme to eradicate (eliminate) hepatitis C. J Hepatol. 
Vol.64 (2 Suppl):S224. 
Martins, J. et al. (2016) Long-Term Effect of the Portuguese Universal 
Access Program to New Generation Direct-Acting Antivirals for the 
Treatment of Hepatitis C. J Hepatol., Vol.64 (2 Suppl): S778 - S779. 
Other Presentation by Secretary of State Prof. Fernando Araújo on Portugal’s 
national strategy and action plan  at meeting on HCV elimination in Portugal 
held at the European Parliament, October 2017.  
Sources of 
information 
Feedback from Domingos Duran and Óscar Duarte (August 2017), 
Ricardo Baptista Leite (October 2017). Updated by National Focal 
Point in March 2018. 
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Romania 
 
Summary: There is currently no official national strategy or action plan addressing hepatitis 
available and no specific document addressing HCV treatment for PWID was identified. A 
draft national strategy on hepatitis B and C is being drafted (October 2017). Only patients 
with health insurance can receive HCV treatment and access to DAAs is limited (until 2015 
only interferon-based regimens were reimbursed). In 2015-2016, about 5000 compensated 
(Fibrosis stage F4) patients were treated with DAAs, while non-cirrhotic (F1-F3) patients were 
only reimbursed when undergoing interferon-based therapies. In March 2017 a contract was 
signed with a pharmaceutical company to purchase DAA treatment for 2000 decompensated 
cirrhotic patients and a further contract is under preparation to expand DAA access to 10.000 
patients with lower fibrosis stages and those at risk of transmitting HCV. The review of DAA 
restrictions criteria in Europe performed on behalf of the International Network on Hepatitis 
in Substance Users (INHSU) Network reported that a negative drug test is required before 
starting DAA treatment for patients co-infected with HIV/HCV (Marshall et al 2018). 
 
HCV policy key-document  
 
No specific document addressing national policy of HCV treatment and care for PWID 
identified. 
 
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Guidelines National Insurance (Nov 2015): PRECIZĂRI PRIVIND ACCESUL LA 
TERAPIA INTERFERON FREE [Requirements for access to interferon 
free therapy] 
HCV research and 
practice  
Prof. Adrian Streinu-Cercel: “HCV Romanian framework” – 
presentation held at the EU Parliament for the MEP “Friends of the 
Liver” meeting focusing on: The Challenge of Hepatitis C in Central 
and South Eastern Europe (22 March 2017)  
Other Ministerul Sanatatii: Strategia Nationala de Sanatate 2014-2020 [The 
National Health Strategy 2014-2020. Document does not specifically 
mention PWID access to HCV treatment and care 
Kautz A, Enescu C., Chavdarova, L. (2013): The Romanian Hepatitis 
Action Paper: „The White Paper of Hepatitis C in Romania – Issues, 
challenges and solutions 2013-2018”,Romanian Liver Patients 
Association (APAH-RO) & European Liver Patients Association (ELPA). 
Document does not specifically mention PWID access to HCV 
treatment and care  
Sources of 
information 
Feedback on summary and list of documents provided by Adrian 
Octavian Abagiu and Lavinius Sava (August 2017) and confirmed by 
National Focal Point Romania (February 2018). 
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Slovakia 
 
Summary: No official national hepatitis policy document (strategy or action plan) currently 
exists.  The current (2013) clinical treatment guidelines state that people who use drugs are 
required to be abstinent for a minimum of six months before starting HCV treatment. This 
limitation also applies also to people in opioid substitution treatment. However, 
hepatologists are in practice following the 2016 EASL recommendations regarding HCV 
treatment and that work is on-going to translate these into Slovak language and adopt them 
as official treatment guidelines. 
 
HCV policy key-document  
 
No specific document addressing national policy of HCV treatment and care for PWID 
identified. 
 
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Guidelines National guideline for Hepatitis C diagnostic and treatment 
(September 2013)  
HCV research and 
practice  
 
Other  
Sources of 
information 
Feedback received from Zuzana Alexandercikova (August 2017). 
Validated by Imrich Steliar, National Focal Point for Slovakia in March 
2018. 
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Slovenia  
 
Summary: A first national strategy for the management of HCV infection was established in 
1999 and already included PWID. Since 2006, regular national conferences to discuss HCV 
management of HCV among PWID were held and in 2009, a specific national guideline for the 
clinical management of HCV was published. A National viral hepatitis expert board reviews 
and updates this guideline on a regular basis. An integrated national network approach to 
treatment of HCV among PWID is implemented with strong coordination between the five 
clinical centers for viral hepatitis treatment and the 18 drug treatment centers in the country. 
These centers also provide prevention activities such as: regularly voluntary testing on HCV, 
promotion of testing, counselling on HCV and HIV, promotion of treatment of HCV and they 
cooperate with several low threshold agencies including those providing syringes and other 
clean drug use equipment. Since 2016, transient elastography is available in the network of 
drug treatment centers and is performed in all HCV-infected PWID, followed by enhanced 
linkage-to care at one of the five regional viral hepatitis treatment centers. In 2015, DAAs 
were introduced for HCV treatment in Slovenia. While clinical guidelines initially included 
restrictions of DAA treatment access, depending on the clinical status (only for patients with 
advanced liver disease, HCC and HIV co-infection) but did not include any restrictions 
regarding drug use, all restrictions for the use of DAAs have been removed since December 
2017, and they became the standard of care for all HCV-infected persons including PWID. 
Since 2011, intensive work has been going on to support the implementation of the HCV 
treatment guidelines for PWID, by presenting and discussing them at various national 
conferences with multi-stakeholder audiences, including addictions specialists, medical 
doctors, patient representatives, national health insurance authorities and medical policy 
makers. With the introduction of mobile units in 2018, testing for HCV, HBV and HIV as well 
as transient elastography will be offered in outreach settings, in order to reach PWID not in 
contact with treatment centers. National guidelines for such diagnosis and linkage-to-care 
are under preparation will be prepared by the National viral hepatitis expert board. 
 
HCV policy key-document  
 
Maticic M, Brinovec V, Lesnicar G, Vidmar L, Meglic-Volkar J: Hepatitis C v Sloveniji. ISIS 1999, 
8:49-51. 
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Guidelines Maticic M, Kastelic A: National guidelines for the management of 
hepatitis C virus infection in drug users in Slovenia. ZdravVestn 2009, 
78:529-539. Regular updates since then. 
HCV research and 
practice  
Maticic 2014: A national multidisciplinary healthcare network for 
treatment of hepatitis C in people who inject drugs in Slovenia BMC 
Infectious Diseases 2014 14(Suppl 6):S6 
Other  
Sources of 
information 
Feedback received from Irena Klavs and Mojca Maticic; updated in 
March 2018 and validated by the National Focal Point for Slovenia. 
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Spain 
 
Summary: The Ministry of Health published the first national plan for responding to hepatitis 
C in the health system in 2015. PWID are mentioned as a key priority group. The current 
national HCV treatment guidelines also date from 2015.  
 
 
HCV policy key-document  
 
Ministry of Health (May 2015): “PLAN ESTRATÉGICO PARA EL ABORDAJE DE LA HEPATITIS C 
EN EL SISTEMA NACIONAL DE SALUD” [Strategic plan for tackling Hepatitis C in the Spanish 
Health System] (and update November 2016, ppt) 
 
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Guidelines AEEH (2015): “Documento del II Consenso español sobre tratamiento 
de la hepatitis C” [Guidelines on HCV treatment]  
HCV research and 
practice  
Roncero et al (2017): “Chronic hepatitis C and individuals with a 
history of injecting drugs in Spain: population assessment, challenges 
for successful treatment”. European Journal of Gastroenterology & 
Hepatology  
Other Several Spanish regions (e.g. Canarias (2014), Catalonia (2003), 
Madrid (2007)) have published regional policy documents (guidelines, 
action plans etc.) – these are referenced in the national strategy. 
Sources of 
information 
Feedback received from Elena Alvarez Martin (May 2017). 
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Sweden 
Summary: No overall strategy or action plan for viral hepatitis exists. However, the national 
board of health published comprehensive guidelines for the prevention of HIV and viral 
hepatitis among people who inject drugs in 2015. Also, the updated HCV treatment 
guidelines from 2016, includes an expanded section on PWID, mentioning specifically the 
need for and challenges with treating active PWID for HCV. In April 2017, a consensus 
document on how to improve HCV treatment among PWID was published by a multi-
disciplinary group of Swedish experts. And in October 2017, the needle-exchange programme 
in Stockholm started offering HCV treatment to its clients.  
 
 
HCV policy key-document  
 
Folkhälsomyndigheten (2015): “Hälsofrämjande och förebyggande arbete med hepatit och 
hiv för personer som injicerar droger. En vägledning” [Guidelines for prevention of hepatitis 
and HIV among people who inject drugs]  
 
 
 
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Guidelines See also national HCV key-document  
National HCV treatment guidelines (2016) “Läkemedelsbehandling av 
hepatit C-virusinfektion hos vuxna och barn 2016 – 
Behandlingsrekommendation”  
HCV research and 
practice  
Alanko Blome, M et al (April 2017) ”Konsensusdokument om 
förbättringar i behandlingen av hepatit C för personer som injicerar 
droger” [Consensus document on improvements in treatment of 
hepatitis C for people who inject drugs] 
Other  
Sources of 
information 
Feedback received from Niklas Karlsson (October 2017). 
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United Kingdom 
 
Summary:  HCV policies in the UK date back to 2002, when England published a first hepatitis 
strategy, followed by a “Hepatitis C Action Plan” in 2004.  The Scottish government launched 
the first phase of its Hepatitis C Action Plan in 2006. This plan has since evolved into a 
comprehensive “Sexual Health and Blood Borne Virus Framework 2015-2020”. Scotland is 
one of the few countries that has a governance body in place to monitor implementation of 
the response to viral hepatitis.  Northern Ireland launched its Action Plan for the Prevention, 
Management and Control of Hepatitis C in 2007. The Welsh Assembly Government brought 
out a Blood Borne Viral Hepatitis Action Plan for Wales in 2010. All national plans address 
PWID. At national level, a multi-agency National Strategic Group on Viral Hepatitis (NSGVH) 
produces a national report ‘Hepatitis in the UK’ which addresses service coverage and impact 
of measures applied. National guidelines on HBV and HCV testing for people at risk of 
infection are published by the National Institute for Health and Care Excellence (NICE) and 
specifically address PWID. There is no restriction regarding access to HCV treatment for PWID 
in the UK. 
 
HCV policy key-document  
 
Public Health England multi-agency National Strategic Group on Viral Hepatitis (NSGVH) 
(2017): Hepatitis C in the UK. 2017 report. Working to eliminate hepatitis C as a major public 
health threat 
 
 
Additional documents illustrating access of PWID to HCV treatment and care: 
Guidelines The National Institute for Health and Care Excellence (NICE) Guidance 
on hepatitis. 
Guideline on “Hepatitis B and C testing: people at risk of infection 
(PH43), Dec 2012 (New NICE guideline under development).  
HCV research and 
practice  
Welsh Government (May 2015), Together for Health: Liver Disease 
Delivery Plan 
Other Department of Health (2002): Hepatitis strategy for England. The 
Department of Health (2004): Hepatitis C Action Plan for England. 
Department of Health, Social Services and Public Safety “Action Plan 
for the Prevention, Management and Control of Hepatitis C in 
Northern Ireland” in 2007. Welsh Government Blood Borne Viral 
Hepatitis Action Plan for Wales 2010- 2015. The Scottish Government: 
Sexual Health and Blood Borne Virus Framework 2015-2020 Update. 
The Scottish Government: Sexual Health and Blood Borne Virus 
Framework 2011-2015.  
Hepatitis C Action Plan for Scotland, Phase II May 2008-March 2011  
Hepatitis C Action Plan for Scotland, 2006  
Sources of 
information 
Feedback received from Vivian Hope (March 2018). 
 
 
 
### 
